HALIFAX, Nova Scotia, January26, 2018 – Appili Therapeutics Inc. (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development and commercialization, today announced that Halifax Chamber of Commerce presented Appili with its 2018 ‘New Business of the Year’ award. The announcement was made during a ceremony at the Halifax Business Awards gala event on Thursday, January 25, 2018, held at the Halifax Convention Centre. Kevin Sullivan, Appili’s Chief Executive Officer, accepted the award on behalf of the Company.
“In the first few years since Appili started, our team has generated a balanced-risk pipeline with three thriving programs, two of which are approaching near-to-market, and could start providing much-needed options for addressing significant unmet medical needs. In our third program, we’ve laid the groundwork to address one of the biggest health crises of our time: antibiotic resistance,” said Kevin Sullivan, MBA, Chief Executive Officer of Appili Therapeutics. “The Chamber of Commerce awards ceremony provided an occasion to recognize not only our successes within Appili, but also the critical component that the Halifax community, and other Canadian resources, have played in our accomplishments. From funding and human capital, to access to cutting-edge academic research and technology, this community has been an integral part of our story.”
The ‘New Business of the Year’ award honours an active business located in Halifax that has been operating for less than two years. Appili was founded by a team of drug development, infectious disease, and commercialization experts to advance the global fight against infectious disease and the mounting threat of drug-resistant pathogens.
About Appili Therapeutics
Appili Therapeutics, Inc., was founded to advance the global fight against infectious disease by matching clearly-defined patient needs with drug development programs that provide solutions to existing challenges patients, doctors and society face in this challenging disease space. Balancing near-to-market product candidates with higher-risk but potentially transformative early-stage programs, Appili’s growing pipeline includes assets being developed by Appili as well as an active licensing program. ATI-1501 employs Appili’s proprietary, taste-masked, oral-suspension technology with metronidazole for the growing number of pediatric and elderly patients with difficulty swallowing. ATI-1503 is a drug discovery program aimed at generating negamycin analogue candidates, a novel class of antibiotics with broad-spectrum activity against Gram-negative bacteria. Via an in-licensing program, Appili acquired the rights to ATI-1701, a vaccine for tularemia, removing risk from a weaponized bioterrorism pathogen. Headquartered in Halifax, Nova Scotia, with offices in Mississauga, Ontario, Appili is pursuing worldwide opportunities in collaboration with science and industry commercial partners, governments and government agencies. For more information, visit www.AppiliTherapeutics.com.
